Dynamic Technology Lab Private Ltd Makes New Investment in DaVita Inc. $DVA

Dynamic Technology Lab Private Ltd bought a new stake in shares of DaVita Inc. (NYSE:DVA) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 10,949 shares of the company’s stock, valued at approximately $1,244,000.

Other large investors have also recently modified their holdings of the company. Elevation Wealth Partners LLC increased its position in shares of DaVita by 147.3% during the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after purchasing an additional 165 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in shares of DaVita during the 2nd quarter valued at approximately $43,000. iSAM Funds UK Ltd bought a new position in shares of DaVita during the 3rd quarter valued at approximately $46,000. Stance Capital LLC bought a new position in shares of DaVita during the 3rd quarter valued at approximately $47,000. Finally, Fideuram Asset Management Ireland dac bought a new position in shares of DaVita during the 4th quarter valued at approximately $49,000. Institutional investors own 90.12% of the company’s stock.

DaVita Trading Up 2.2%

Shares of DVA stock opened at $208.31 on Friday. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $211.80. The stock has a market capitalization of $13.37 billion, a price-to-earnings ratio of 19.32, a P/E/G ratio of 0.67 and a beta of 0.91. The stock has a fifty day simple moving average of $176.13 and a two-hundred day simple moving average of $146.09.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The business had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.36 billion. During the same period in the prior year, the business earned $2.00 EPS. The business’s revenue for the quarter was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Research analysts predict that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on DVA. UBS Group boosted their target price on DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. TD Cowen boosted their target price on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research report on Monday, May 11th. Barclays upped their price objective on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Finally, Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, DaVita has an average rating of “Hold” and a consensus price target of $199.17.

Insider Buying and Selling at DaVita

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the sale, the chief financial officer directly owned 132,434 shares in the company, valued at approximately $25,440,571.40. This represents a 27.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.